ArticleJournal of the American Heart Association2025
Effect of Statins in Patients With Hemodialysis-Dependent Chronic Kidney Disease: A Nationwide Cohort Study.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipid Disorders in Patients with Renal Failure: Role in Cardiovascular Events and Progression of Chronic Kidney Disease.Life (Basel, Switzerland) · 2026Review
- Simvastatin Mitigates Kidney Injury via Inhibition of the TNF-α/α-SMA Signaling Pathway in a Subtotal Nephrectomy Model.Journal of experimental pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuidelines for lipid-lowering therapy in patients with dialysis-dependent chronic kidney disease remain ambiguous. We aimed to explore cardiovascular outcomes associated with statin use in patients with hemodialysis-dependent chronic kidney disease, stratified by prior statin use.
methodsThis was a retrospective cohort study of patients with chronic kidney disease who initiated maintenance hemodialysis, using a nationwide health claims database in Korea between 2010 and 2021. A multivariate Cox regression analysis was performed, incorporating statin use throughout the follow-up period as a time-dependent variable. The primary outcome was a composite of stroke, myocardial infarction, and all-cause mortality. A subgroup analysis was conducted based on statin use before hemodialysis initiation.
resultsOf the 49 868 study participants, the mean age at hemodialysis initiation was 65.5±11.2 years, and 32 225 (64.6%) were men. During a mean follow-up of 3.8 years, the primary composite outcome occurred in 20 345 patients (40.8%). Throughout the follow-up period, approximately 40% of patients received statin therapy. Statin use was significantly associated with a reduced risk of the primary composite outcome (adjusted hazard ratio, 0.51 [95% CI, 0.49-0.53];
conclusionsStatin use was consistently associated with improved long-term cardiovascular outcomes in patients with hemodialysis-dependent chronic kidney disease, regardless of prior statin use. These findings suggest that continuing statin therapy is crucial for cardiovascular prevention in patients already receiving statins before hemodialysis initiation; initiating statin therapy may also provide clinical benefits in statin-naïve patients undergoing hemodialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.